Business Wire

GA-FINEOS

28.1.2021 15:17:12 CET | Business Wire | Press release

Share
FINEOS Achieves Unprecedented Client Go Live Success in 2020

FINEOS Corporation (ASX:FCL ) continues to demonstrate its long standing purpose to “help our clients care for the people they serve through the delivery of superior insurance technology” in 2020 with the completion of 8 new installations and 7 major upgrades of the FINEOS Platform . As a leading provider of core systems for life, accident and health insurers globally, FINEOS offers unparalleled core solutions that help carriers become more dynamic, scalable and competitive.

“We are pleased with our performance over the past year, especially given the challenges we all face in these times of COVID,” said Michael Kelly , CEO of FINEOS. “Many of our global clients are actively engaged in brand-new installations, version upgrades and platform migrations. This tells us that our clients see the value of our significant R&D investment made over the past 5 years and indeed are modernizing their core systems in support of their digital transformation. We are grateful to our clients and SI partners for the tremendous implementation and upgrade achievements over the past year.”

By upgrading to the SaaS-based FINEOS Platform, clients will reap the benefits of a more modern and comprehensive unified system for integrated absence, group and voluntary benefits.

“The FINEOS Platform is purpose built to support the Employee Benefits market and therefore provides several advantages to our clients over repurposed P&C core systems,” said Chuck Johnston , CMO of FINEOS. “As a result, our clients enjoy easier installations and upgrades. What’s more, innate policy and customer management capabilities that exist across the entire FINEOS Platform provide consistent product information as well as powerful, frictionless process and workflows across the platform. These foundational capabilities are distinctive to the FINEOS Platform market offerings from claims to Integrated Disability and Absence Management (IDAM) to the full FINEOS AdminSuite which enables clients to move to quote to claim on one system.”

Demonstrated client success metrics include:

  • 40% improvement in staff satisfaction in billing and policy admin
  • 27% reduction in disability duration
  • 10% increase in client on-time contact
  • 25% increase in claim settlements per day
  • 12% improvement in RTW (Return to Work)
  • 93% reduction for claims acceptance time: now accepted within five days of an accident, down from seventy

Since the start of the COVID-19 pandemic, Employee Benefits carriers in North America and protection schemes across the globe have seen increased demand from their customers for new products, remote functionality, and faster processing times that cannot be achieved with legacy systems.

The value of the FINEOS Platform with excellent client support is evident in the company’s long-term partnerships. “Our partnership with FINEOS continues to grow and we are realizing benefits from the FINEOS system, including streamlined processes which enable our managers to focus on providing excellent outcomes to QSuper members,” said Phil Frazer , CEO of QInsure, Australia. “We are excited to continue our partnership with FINEOS to help support our organization’s agility, digital customer experience and our service excellence.”

In North America, where claims and paid leave laws continue to reverberate with change due to COVID, the necessity for carriers to embrace Integrated Disability and Absence Management (IDAM) remains a critical path to future success. Throughout 2020, FINEOS continued to focus on integrated absence management as a core capability, helping carriers simplify the complex process of managing absence to improve engagement and user experience. As the industry leader for core software, FINEOS plans to raise the industry standard in 2021 even further by continually expanding the FINEOS Platform for Employee Benefits.

“Insurers need technology solutions to meet the increased expectations for customer experience and to increase efficiencies and outcomes for key products like Disability and Absence Management,” says Nancy Casbarro , Vice President of Research and Consulting at Novarica. “They’re looking to solution providers like FINEOS for solutions that offer digital solutions for self-service, configurable policy administration, enrollment and claims capabilities all driving greater efficiency, reliable upgrades and long-term system lifecycle support.”

About FINEOS Corporation

FINEOS is a leading provider of core systems for life, accident and health insurers globally with 7 of the 10 largest group life and health carriers in the US as well as 6 of the largest life insurers in Australia. With employees and offices throughout the world, FINEOS continues to scale rapidly, working with innovative progressive insurers in North America, Europe, and Asia Pacific.

The FINEOS Platform provides core administration capabilities including absence management, billing, claims, payments, policy administration, provider management and new business and underwriting; all of which are configurable to operate independently or as FINEOS AdminSuite, an end-to-end core administration suite.

For more information, visit www.FINEOS.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Wyss Geneva Steps Into Its Next Chapter11.6.2026 13:33:00 CEST | Press release

Dr. Tracy Laabs named Director; Prof. Dr. Erwin Böttinger honored for his transformative leadership The Wyss Center for Bio and Neuroengineering in Geneva is pleased to announce the appointment of Dr. Tracy Laabs as Director, effective July 1st 2026. Dr. Laabs succeeds Prof. Dr. Erwin Böttinger, who leaves behind a fundamentally transformed organization: one that no longer just pursues breakthrough science but systematically turns it into ventures that reach patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611328520/en/ Dr. Tracy Laabs, incoming Director, Wyss Center Geneva Since joining the Wyss Center as Director in April 2023, Prof. Böttinger brought a bold vision: to evolve the Center from a portfolio of promising projects into a disciplined engine for venture creation. Under his leadership, the Center spun off six companies in two years (including ABILITY Neurotech SA and Clee Medical SA in 2025) while simult

BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit11.6.2026 13:24:00 CEST | Press release

Nearly two-thirds of patients aged 80+ treated with BRUKINSA remained progression-free at six years, despite advanced age and high-risk featuresNew European patient research reveals safety, disease severity, and effectiveness are the top drivers for first-line CLL treatment decisions – not time on therapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) aged 80 and older, showing sustained benefit with BRUKINSA after nearly 6.5 years of follow-up, reinforcing its role as the foundational BTK inhibitor. BRUKINSA is the only BTK inhibitor to demonstrate superior efficacy vs. ibrutinib in a Phase 3 trial.1 These data, one of the largest datasets of older patients with treatment-naive CLL, will be presented at the 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden. Amit Agarwal, M.D.,

Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations11.6.2026 13:00:00 CEST | Press release

Once-daily oral zasocitinib demonstrated statistical superiority over deucravacitinib for all primary and key secondary endpoints in plaque psoriasis study More than 35% of zasocitinib-treated patients achieved complete skin clearance (PASI 100) at week 16 – more than 2.5 times the response rate for deucravacitinib Safety profile was consistent with previous studies with no new safety signals identified Takeda (TSE:4502/NYSE:TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib in adults with moderate-to-severe plaque psoriasis (PsO). In the LATITUDE Atlas (TAK-279-PsO-3004) head-to-head study, zasocitinib demonstrated statistical superiority over deucravacitinib for the primary endpoint, Psoriasis Area and Severity Index (PASI) 100 response rate at week 16. The study also demonstrate

Clearlake Expands Liquid Credit Platform With Acquisition of LCM Asset Management’s CLO Contracts11.6.2026 13:00:00 CEST | Press release

Transaction adds 31 CLOs and more than $5 billion of AUM, strengthening Clearlake Credit’s position in liquid credit Clearlake Capital Group, L.P. (“Clearlake” or the “Firm”), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies, today announced that its credit platform, Clearlake Credit, will assume management of CLOs managed by LCM Asset Management, LLC. The transaction adds 31 CLOs representing more than $5 billion of assets under management and increases assets managed by Clearlake Credit to approximately $39 billion across liquid credit, private credit, and other customized credit solutions. The acquisition further broadens the Firm’s capabilities, deepens its relationships with institutional investors, and reinforces its client-centric approach and commitment to seeking attractive risk-adjusted returns across market cycles. Milbank LLP and Dechert LLP represented Clearlake Credit in the transaction

L&T Technology Services, Databricks Partner to Deliver Industrial AI at Scale for Asset-Intensive Industries11.6.2026 12:30:00 CEST | Press release

Partnership brings together LTTS’ expertise in its Sustainability segment and the Databricks platform to accelerate Engineering Intelligence across industrial operations. L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, today announced a strategic go-to-market partnership with Databricks, the leading Data and AI company, to co-develop and deliver Industrial AI solutions that advance Engineering Intelligence (EI) for asset-intensive enterprises. Anchored in LTTS' Sustainability segment, spanning Process Engineering, Discrete Manufacturing and Industrial Products, the partnership will support Energy, Petrochemicals and Industrials clients globally. As industrial organizations seek to unlock greater value from decades of operational and engineering data, the alliance will combine LTTS’ deep domain capabilities with the Databricks platform to transform complex plant data into Engineering Intelligence - enabling improved asset reli

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye